Naprosyn
Naprosyn Price range: $ 56,00 through $ 260,00
Back to products
Natrise
Natrise Price range: $ 45,00 through $ 115,00

Nasonex nasal spray

Price range: $ 62,00 through $ 276,00

Nasonex Nasal Spray is an effective corticosteroid medication designed to provide powerful relief from bothersome seasonal and year-round allergy symptoms. It works by reducing inflammation in the nasal passages to alleviate congestion, sneezing, and an itchy or runny nose. This targeted formula is also officially indicated for the treatment of nasal polyps in adults, helping to decrease swelling and improve breathing. The non-drowsy spray delivers consistent results, allowing you to maintain your daily routine without the discomfort of persistent respiratory allergies. With its long-lasting action, Nasonex helps manage your symptoms throughout the day and night for enhanced comfort.

SKU: Nasonex nasal spray Category:
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Nasonex nasal spray belongs to the therapeutic class of nasal corticosteroids, designed to reduce inflammatory reactions directly within the nasal mucosa. It contains mometasone furoate monohydrate at a metering dose delivering 50 mcg of active medication per actuation. In the United States, this formulation is available over the counter for adults and children aged 2 years and older to manage indoor and outdoor nasal allergy symptoms.

Unlike oral antihistamines that block systemic histamine H1 receptors, topically applied intranasal corticosteroids suppress multiple inflammatory cell types and chemical mediators directly inside the nasal passages. Understanding proper administration techniques and expected therapeutic timelines helps optimize treatment outcomes while minimizing localized adverse effects.

Attribute Product Details
Drug name Nasonex Nasal Spray
Active ingredient Mometasone furoate monohydrate (50 mcg/actuation)
Therapeutic class Nasal corticosteroid (AHFS: Anti-inflammatory agents)
Dosage form Nasal spray suspension
Route of administration Intranasal
Primary purpose Temporary relief of allergic rhinitis symptoms

Clinical Profile and Practical Use

How the drug works

Mometasone furoate is a synthetic corticosteroid demonstrating potent local anti-inflammatory activity. At the cellular level, glucocorticoids cross cell membranes and bind to intracellular glucocorticoid receptors. This ligand-receptor complex interacts with DNA to inhibit the transcription of inflammatory cytokines, chemokines, and inflammatory enzymes. On one hand, oral decongestants constrict blood vessels systemically; on the other hand, intranasal mometasone acts locally on nasal mucosal tissue to inhibit mast cells, eosinophils, neutrophils, and basophils. Consequently, it decreases the release of histamine, leukotrienes, and prostaglandins, directly reducing mucosal edema, hypersecretion, and nasal airway resistance.

What it’s used for

Nasonex is indicated for the temporary relief of symptoms associated with seasonal allergic rhinitis (hay fever) and perennial (year-round) allergic rhinitis. Key nasal symptoms managed by this product include congestion, sneezing, runny nose (rhinorrhea), and nasal itching. It is approved for adult and pediatric populations aged 2 years and older. For individuals with known seasonal allergies, initiating daily treatment shortly before the anticipated start of the pollen season helps attenuate the onset and severity of inflammatory nasal symptoms.

What you may notice early on

Unlike immediate-acting vasoconstrictive decongestant sprays, Nasonex does not provide instant symptom relief upon initial application. Some individuals may observe initial symptom reduction within 12 hours after the first administration. However, the maximum anti-inflammatory benefit typically develops over several days of continuous daily use, with peak efficacy achieved within 1 to 2 weeks. Patients transitioning from rapid-acting remedies should maintain consistent daily administration rather than applying the spray on an intermittent, as-needed basis.

Dosing schedule

Dosing is determined by age and individual therapeutic response. For adults and adolescents aged 12 years and older, the standard starting dosage is 2 sprays in each nostril once daily (total daily dose of 200 mcg). Once symptoms are adequately controlled, reducing the dose to 1 spray in each nostril once daily (total daily dose of 100 mcg) may serve as an effective maintenance regimen. For pediatric patients aged 2 to 11 years, the standard dose is 1 spray in each nostril once daily (total daily dose of 100 mcg). The bottle must be gently shaken prior to each use and primed with 10 test sprays before initial application or if unused for 14 consecutive days.

Practical tips

To ensure optimal drug delivery and avoid localized nasal trauma, gently blow the nose to clear the nasal passages prior to administration. Tilt your head slightly forward, insert the bottle nozzle into one nostril while occluding the opposite nostril, and point the spray tip slightly outward toward the outer corner of the eye (away from the central nasal septum). Depress the pump fully while breathing in gently through the nose. Avoid spraying directly onto the nasal septum, as direct impact increases the risk of nosebleeds and tissue irritation. Wipe the nozzle clean with a dry tissue after use and replace the dust cap immediately.

How it’s absorbed and eliminated

Following intranasal administration of mometasone furoate at recommended therapeutic doses, systemic bioavailability is extremely minimal (less than 1%). Plasma concentrations of mometasone furoate remain below the lower limit of quantification (50 pg/mL) in most individuals. Any portion of the dose that is swallowed undergoes extensive hepatic first-pass metabolism prior to entering systemic circulation. The minute fraction of drug absorbed into systemic circulation exhibits high plasma protein binding (98% to 99%). Absorbed mometasone is extensively metabolized into multiple metabolites via cytochrome P450 3A4 (CYP3A4) pathways and excreted primarily via feces and urine.

Common Questions and Safety Considerations

Adverse reactions

Nasonex is generally well-tolerated due to minimal systemic absorption, though localized mucosal adverse events can occur. Common mild reactions include headache, local nasal irritation, pharyngitis (throat irritation), coughing, and minor epistaxis (nosebleeds). On one hand, nasal steroids avoid the central nervous system drowsiness associated with first-generation oral antihistamines; on the other hand, improper spray direction or long-term mechanical irritation can cause localized mucosal breakdown. Rare adverse reactions reported include nasal septal ulceration, localized burning, and altered sense of taste or smell (dysgeusia/osmia). Persistent epistaxis requires clinical re-evaluation.

Compatibility with other medicines

Because systemic exposure to mometasone furoate is negligible after intranasal application, systemic drug interactions are uncommon. However, caution is advised when co-administering potent cytochrome P450 3A4 (CYP3A4) inhibitors. Strong CYP3A4 inhibitors (such as ketoconazole, itraconazole, ritonavir, or clarithromycin) can decrease mometasone clearance, potentially increasing systemic corticosteroid exposure. While concurrent administration with oral non-sedating antihistamines or saline nasal rinses is compatible, combining multiple steroid treatments (such as systemic or inhaled corticosteroids) increases the total corticosteroid burden and requires professional supervision.

Important precautions

Careful clinical evaluation is warranted in patients with recent nasal septal ulcers, recent nasal surgery, or nasal trauma, as corticosteroids impair wound healing. Systemic corticosteroid effects–including hypercorticism, adrenal suppression, or pediatric growth velocity reduction–are rare with intranasal therapy, but long-term exposure to high doses warrants periodic monitoring. Periodic ophthalmic evaluations are advised for patients with a history of elevated intraocular pressure, glaucoma, or cataracts, as topical corticosteroids can potentially exacerbate ocular conditions. Caution is also advised in individuals with active or latent tuberculous infections, untreated fungal or bacterial infections, or ocular herpes simplex due to potential localized immunosuppression.

Available alternatives

When selecting allergy therapy, patients often evaluate intranasal corticosteroids against other therapeutic options. Compared with oral antihistamines, which rapidly target systemic symptoms like ocular itching and sneezing but show limited efficacy against severe blockage, intranasal mometasone provides broad anti-inflammatory action that directly targets nasal tissue swelling. Compared with topical nasal decongestants (such as oxymetazoline), intranasal mometasone does not carry the risk of rebound nasal congestion (rhinitis medicamentosa) when used daily. However, unlike fast-acting decongestants, mometasone requires continuous daily administration over several days to establish peak efficacy.

If you skip a dose

If a daily dose of Nasonex is missed, administer the spray as soon as remembered on that day. If it is nearly time for the next scheduled dose, skip the missed dose and resume the standard daily administration schedule. Do not double the number of sprays or take extra doses to compensate for a missed application. Maintaining a regular, consistent daily schedule supports optimal symptom suppression while minimizing local tissue irritation.

Safety Precautions & Red Flags

Symptom / Red Flag Recommended Action
Swelling of the face, lips, tongue, or throat Seek immediate emergency medical attention (severe allergic response)
Severe or continuous nosebleeds (epistaxis) Discontinue use and consult a healthcare professional
Visible nasal sores or persistent septal pain Stop application and obtain a nasal examination
Vision changes, ocular pain, or blurred vision Schedule an eye examination with an ophthalmologist
Signs of localized infection (fever, purulent nasal discharge) Consult a healthcare provider for diagnosis

Frequently Asked Questions

Can Nasonex cause rebound congestion if used for several weeks?

No. Rebound congestion (rhinitis medicamentosa) occurs primarily with topical nasal decongestants (such as oxymetazoline) when used for more than 3 to 5 consecutive days. Nasonex is an intranasal corticosteroid that does not cause rebound mucosal swelling, making it safe for continuous daily management throughout an allergy season under appropriate product guidelines.

How long does it take for Nasonex to start relieving nasal allergy symptoms?

Some individuals notice initial symptom relief within 12 hours of the first dose. However, maximum anti-inflammatory benefits typically build up gradually over 1 to 2 weeks of consistent daily application. Regular daily administration is necessary to maintain therapeutic benefit.

What should I do if I experience minor nosebleeds after spraying?

Minor nosebleeds (epistaxis) often occur if the spray nozzle is directed toward the central wall of the nose (the nasal septum). Ensure the nozzle tip is angled outward toward the outer corner of your eye during administration. If nosebleeds persist despite proper technique, pause treatment and consult a healthcare provider.

Can Nasonex be used alongside an oral allergy medication?

Yes, intranasal corticosteroids are frequently used in combination with oral non-sedating antihistamines when monotherapy provides incomplete symptom control. Consult a pharmacist or doctor to confirm that your combined regimen is appropriate for your specific situation.

Is it safe to use Nasonex during pregnancy or while breastfeeding?

Systemic absorption of mometasone furoate following intranasal application is minimal (less than 1%). However, pregnant or nursing individuals should consult their healthcare provider to evaluate individual benefits and risks before starting treatment.

In accordance with FDA requirements.

This text is for informational purposes only and does not constitute individual medical advice.

Additional information
Dosage

18g

Package

2 sprayer

,

3 sprayer

,

4 sprayer

,

5 sprayer

,

6 sprayer

,

7 sprayer

,

8 sprayer

,

9 sprayer

,

10 sprayer

Ενεργός Ουσία